Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

There have been tremendous strides looking at different immune-based platforms, states Slovin. An approach being evaluated is the PROSTVAC platform, which is a transgene of PSA in a fowlpox vector given with 3 immune stimulatory molecules.

There are a variety of molecules to which immunotherapies are being developed including VISTA, LAG-3, FoxP3, explains Slovin.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Prostate Cancer

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Slovin on the Future of Immunotherapy in Prostate Cancer